Compare Amphastar Pharmaceuticals Inc (AMPH) vs American Express Co (AXP) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

American Express (AXP) trades at $350.58, up 1.11% today, with a bullish technical signal and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and the company is expanding its premium cardholder perks and AI initiatives, including a new NFL partnership and headquarters development at 2 World Trade Center.

The outlook is positive with a consensus price target of $375.27, implying 7% upside. Risks include economic sensitivity and competitive pressures, but robust consumer spending and innovation in digital payments support growth. Analyst sentiment is mixed with 38.6% buy ratings, highlighting potential for steady gains amid macroeconomic uncertainty.